Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts.

During the past decade, Dana-Farber/ Partners Cancer Care, Inc. conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dana-Farber/ Partners Cancer Care, Inc." #1 sponsor was "Celgene" with 2 trials, followed by "Bicara Therapeutics" with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored, "Matthew Galsky" with 1 trials sponsored and "Northwestern University" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dana-Farber/ Partners Cancer Care, Inc." #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator, "National Cancer Institute (NCI)" with 1 trials as a collaborator, "Pfizer" with 1 trials as a collaborator and "University of California, San Francisco" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Dana-Farber/ Partners Cancer Care, Inc." are "Multiple Myeloma" (2 trials), "Advanced or Metastatic Solid Tumors" (1 trials), "Carcinoma, Squamous Cell" (1 trials), "Colorectal Cancer" (1 trials) and "Cutaneous Squamous Cell Carcinoma" (1 trials). Many other conditions were trialed in "Dana-Farber/ Partners Cancer Care, Inc." in a lesser frequency.

Most popular intervention types in "Dana-Farber/ Partners Cancer Care, Inc." are "Drug" (7 trials), "Biological" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (2 trials), "Durvalumab" (2 trials), "Pomalidomide" (2 trials), "BCA101" (1 trials) and "Cobimetinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dana-Farber/ Partners Cancer Care, Inc." are 5 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Dana-Farber/ Partners Cancer Care, Inc.". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Dana-Farber/ Partners Cancer Care, Inc., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Dana-Farber/ Partners Cancer Care, Inc., 3 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".